Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases: a systematic review and meta-analysis.

Purpose: To conduct a systematic review and meta-analysis of publications to evaluate the analgesic efficacy and safety of percutaneous thermal ablation (PTA) plus percutaneous cementoplasty (PCP) (PTA + PCP) for painful bone metastases.
Methods: We searched PubMed, Cochrane Library and Embase for articles published up to October 2022. Outcomes were a 10-point pain scale, morphine equivalents daily dose (MEDD) and complications. A subgroup confined to spinal bone metastases was analyzed.
Results: Twenty-one articles were selected for the analysis. The 21 selected articles involved a total of 661 cases. The pooled pain scales at pre-PTA + PCP, 1 day, 1 week and 1-, 3-, and 6 months post-PTA + PCP were 7.60 (95% confidence interval [CI], 7.26-7.95, I ²  = 89%), 3.30 (95% CI, 2.25-4.82, I ²  = 98%), 2.58 (95% CI, 1.99-3.35, I ²  = 94%), 2.02 (95% CI, 1.50-2.71, I ²  = 93%), 1.78 (95% CI, 1.26-2.53, I ²  = 95%), and 1.62 (95% CI, 1.14-2.31, I ²  = 88%), and in the subgroup, 7.97 (95% CI, 7.45-8.52, I ²  = 86%), 3.01 (95% CI, 1.43-6.33, I ²  = 98%), 2.95 (95% CI, 1.93-4.51, I ²  = 95%), 2.34 (95% CI, 1.82-3.01, I ²  = 68%), 2.18 (95% CI, 1.57-3.03, I ²  = 78%), and 2.01 (95% CI, 1.16-3.48, I ²  = 86%). Mean MEDD decreased up to 3 months post-PTA + PCP in 4 articles. The overall pooled major complication rate was 4% (95% CI, 2-6%, I ²  = 2%).
Conclusions: The updated systematic review and meta-analysis indicates that PTA + PCP for painful bone metastases is safe, and can lead to rapid and sustained pain reduction.
(© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)